SCHEMBL4576529

SCHEMBL4576529

CC(C)c1c(OC(=O)CCl)cc(C=Cc2ccccc2)cc1OC(=O)CCl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 1/20 0.51
TOP2A P11388 2/20 0.46
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42
TUBA1B P68363 1/20 0.42
TUBA4A P68366 1/20 0.42
TUBB4B P68371 1/20 0.42
TUBB3 Q13509 1/20 0.42
TUBB2A Q13885 1/20 0.42
TUBB8 Q3ZCM7 1/20 0.42
TUBA3E Q6PEY2 1/20 0.42
TUBA1A Q71U36 1/20 0.42
TUBA1C Q9BQE3 1/20 0.42
TUBB6 Q9BUF5 1/20 0.42
TUBB2B Q9BVA1 1/20 0.42
TUBB1 Q9H4B7 1/20 0.42
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL918612 1.00 AHR (0.51) AHRTOP2ALMNAL3MBTL1TUBB4A
SCHEMBL24988875 0.85 AHR (0.50) AHRLMNAL3MBTL1TUBB4ATUBB
SCHEMBL918688 0.84 AHR (0.55) AHRLMNAL3MBTL1TUBB4ATUBB
SCHEMBL918690 0.84 AHR (0.55) AHRLMNAL3MBTL1TUBB4ATUBB
SCHEMBL24988865 0.83 AHR (0.48) AHRLMNAL3MBTL1TUBB4ATUBB
SCHEMBL918444 0.81 TOP2A (0.45) TOP2ATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4576532 0.80 KMT2A (0.40) AHRTOP2ALMNAL3MBTL1TUBB4A
SCHEMBL24988849 0.80 AHR (0.45) AHRLMNAL3MBTL1TUBB4ATUBB
SCHEMBL5182132 0.80 TUBB4A (0.49) TOP2ALMNAL3MBTL1TUBB4ATUBB
SCHEMBL24988853 0.79 AHR (0.47) AHRLMNAL3MBTL1TUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255245-A1 Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxystilbenes and Novel Stilbene Derivatives and Analogues WELICHEM BIOTECH INC. (CA) 2008-10-16 US disclosed
US-7321050-B2 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues WELICHEM BIOTECH INC. (CA) 2008-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255245-A1 Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxystilbenes and Novel Stilbene Derivatives and Analogues NFKBIA, IKBKB, IKBKE AHR 1017/4885TOP2A 3891/4885LMNA 4070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.